Author

Katherine L. Lev

University of MichiganORCID 0000-0002-8612-0972Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:E. coli· 1 Approach:experimental assay· 1 Approach:machine learning (classical)· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

David H. ShermaniD· 2 shared Aaron M. RobidaiD· 1 shared Awet Alem TeklemichaeliD· 1 shared Brian J. CurtisiD· 1 shared Christina M. McBrideiD· 1 shared Debmalya Sarkar· 1 shared Erin N. OliphantiD· 1 shared Fengrui QuiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

David H. ShermanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologyCommunications ChemistryPeer-reviewedDec 5, 2025

Metabolic engineering and late-stage functionalization expand the chemical space of the antimalarial premarineosin A

Christina M. McBride, Morgan McCauley, Natalia R. Harris…·David H. Sherman

This study uses metabolic engineering and late-stage functionalization to expand the chemical diversity of the antimalarial compound premarineosin A, identifying potent analogs.

2 citations

experimental assaydrug response / drug discovery

𝕏 PostBluesky

Systems BiologybioRxivPreprintNov 25, 2024

Ultra-high-throughput screening of antimicrobial combination therapies using a two-stage transparent machine learning model

Margaret M. Reuter, Katherine L. Lev, Jon Albo…·Sriram Chandrasekaran

This paper introduces M2D2, a two-stage ML model that identifies synergistic antimicrobial drug combinations and validates them experimentally against E. coli.

7 citations

E. colimetabolomics

𝕏 PostBluesky